loading page

Decreased Severity and Incidence of SARS-CoV-2 infection in younger patients with bone marrow failure: Description of 4 clinical cases.
  • +9
  • Paul Castillo,
  • Farid Boulad,
  • Monica Bhatia,
  • Staci Arnold,
  • Jeffrey Lipton,
  • Winfred Wang,
  • Jason Farrar,
  • Vandy Black,
  • Carolyn Bennett,
  • Akiko Shimamura,
  • Peter Kurre,
  • Adrianna Vlachos
Paul Castillo
University of Florida

Corresponding Author:[email protected]

Author Profile
Farid Boulad
Memorial Sloan Kettering Cancer Center
Author Profile
Monica Bhatia
Columbia University Medical Center
Author Profile
Staci Arnold
Aflac Cancer and Blood Disorders Center Children's Healthcare of Atlanta Emory University
Author Profile
Jeffrey Lipton
Cohen Children's Medical Center
Author Profile
Winfred Wang
St Jude Children's Research Hospital
Author Profile
Jason Farrar
University of Arkansas for Medical Sciences
Author Profile
Vandy Black
University of Florida
Author Profile
Carolyn Bennett
Children's Healthcare of Atlanta
Author Profile
Akiko Shimamura
Boston Children's Hospital
Author Profile
Peter Kurre
The Children's Hospital of Philadelphia
Author Profile
Adrianna Vlachos
Cohen Children's Medical Center
Author Profile


The Coronavirus Disease 2019 pandemic, caused by the severe acute respiratory syndrome-associated coronavirus (SARS-CoV-2), is having devastating effects on every country around the world. SARS-CoV-2 can be fatal in patients with described risk factors. A question remains as to whether other immunosuppressed populations are at risk for severe complications. There is limited data on the impact of COVID-19 in young patients with bone marrow failure syndromes (BMFs). 29 institutions, from the NAPAAC consortium, reported 4 with BMFs diagnosed with SARS-CoV-2. These patients presented with relatively mild clinical courses, raising questions as to why this apparently low morbidity and mortality